thalidomide has been researched along with Histiocytosis in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Histiocytosis: General term for the abnormal appearance of histiocytes in the blood. Based on the pathological features of the cells involved rather than on clinical findings, the histiocytic diseases are subdivided into three groups: HISTIOCYTOSIS, LANGERHANS CELL; HISTIOCYTOSIS, NON-LANGERHANS-CELL; and HISTIOCYTIC DISORDERS, MALIGNANT.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated thalidomide as a single agent in myeloma, myelodysplastic syndromes (MDS) and histiocytosis, i." | 7.71 | Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. ( Alietti, A; Bertolini, F; Burlini, A; Cineri, S; Cinieri, S; Cocorocchio, E; Corsini, C; Ferrucci, PF; Mancuso, P; Martinelli, G; Mingrone, W; Peccatori, F; Zucca, E, 2001) |
| "Treatment with thalidomide stopped the progression of the disease in two cases." | 5.91 | Progressive mucinous histiocytosis treated successfully with thalidomide: a rare case report. ( Abdollahimajd, F; Diab, R; Kaddah, A; Rakhshan, A; Shahidi Dadras, M, 2023) |
| "We evaluated thalidomide as a single agent in myeloma, myelodysplastic syndromes (MDS) and histiocytosis, i." | 3.71 | Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. ( Alietti, A; Bertolini, F; Burlini, A; Cineri, S; Cinieri, S; Cocorocchio, E; Corsini, C; Ferrucci, PF; Mancuso, P; Martinelli, G; Mingrone, W; Peccatori, F; Zucca, E, 2001) |
| "Treatment with thalidomide stopped the progression of the disease in two cases." | 1.91 | Progressive mucinous histiocytosis treated successfully with thalidomide: a rare case report. ( Abdollahimajd, F; Diab, R; Kaddah, A; Rakhshan, A; Shahidi Dadras, M, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diab, R | 1 |
| Shahidi Dadras, M | 1 |
| Rakhshan, A | 1 |
| Kaddah, A | 1 |
| Abdollahimajd, F | 1 |
| Tóth, B | 1 |
| Katona, M | 1 |
| Hársing, J | 1 |
| Szepesi, A | 1 |
| Kárpáti, S | 1 |
| Hu, X | 1 |
| Liu, J | 1 |
| Bai, C | 1 |
| Wang, J | 1 |
| Song, X | 1 |
| Saano, V | 1 |
| Bertolini, F | 1 |
| Mingrone, W | 1 |
| Alietti, A | 1 |
| Ferrucci, PF | 1 |
| Cocorocchio, E | 1 |
| Peccatori, F | 1 |
| Cinieri, S | 1 |
| Mancuso, P | 1 |
| Corsini, C | 1 |
| Burlini, A | 1 |
| Zucca, E | 1 |
| Martinelli, G | 1 |
| Cineri, S | 1 |
1 review available for thalidomide and Histiocytosis
| Article | Year |
|---|---|
[New therapeutic application of thalidomide].
Topics: Autoimmune Diseases; Colitis, Ulcerative; Erythema Multiforme; Female; Histiocytosis; Humans; Immuno | 1996 |
4 other studies available for thalidomide and Histiocytosis
| Article | Year |
|---|---|
Progressive mucinous histiocytosis treated successfully with thalidomide: a rare case report.
Topics: Adult; Female; Histiocytosis; Humans; Skin Diseases; Skin Neoplasms; Thalidomide | 2023 |
Indeterminate cell histiocytosis in a pediatric patient: successful treatment with thalidomide.
Topics: Adolescent; Histiocytosis; Humans; Immunosuppressive Agents; Male; Skin Diseases; Thalidomide; Treat | 2012 |
Bortezomib combined with thalidomide and dexamethasone is effective for patient with crystal-storing histiocytosis associated with monoclonal gammopathy of undermined significance.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; | 2012 |
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Endothelial Growth Factors; Fem | 2001 |